Spectrum Health Helen DeVos children's hospital	Physician's Orders ABATACEPT (ORENCIA PEDIATRIC, OUTPATIEI INFUSION CENTER Page 1 of 3	I MRN						
 Defaults for orders not otherwise specified below: INITIAL DOSES: Interval: Every 14 days x 2 treatments MAINTENANCE DOSES: Interval: Every 28 days (starting on Day 28 after second initial dose) 								
Duration: Until date: Until date: I year I# of Treatment								
Anticipated Infusion Date_	ICD 10 Code with Des	cription						
Height(cm	n) Weight(kg) Allergies_							
Provider Specialty								
□ Allergy/Immunology		□ OB/GYN	□ Rheumatology					
Cardiology	□ Internal Med/Family Practice	□ Other	□ Surgery					
☐ Gastroenterology ☐ Genetics	□ Nephrology □ Neurology	☐ Otolaryngology ☐ Pulmonary	□ Urology □ Wound Care					
Site of Service								
□ SH Gerber	□ SH Lemmen Holton (GR)	□ SH Pennock	□ SH United Memorial					
□ SH Helen DeVos (GR)	□ SH Ludington	□ SH Reed City	□ SH Zeeland					
Infusion and possible scheduling MAINTEN Safety Parameters and Spec	ted: S, Expires: S+365, Sched. Tolerance: Sche labs. Verify that all INDUCTION/LOADING DOS ANCE DOSES. ial Instructions RAMETERS AND SPECIAL	ES have been scheduled and o						
Provider Reminder								
ONC PROVIDER Premedication is not r Plan.	REMINDER 4 required. For symptoms of allergic reaction or ar	aphylaxis, order "Peds Hyperse	nsitivity Reactions" Therapy					
Treatment Parameters								
Complete Blood C								
Comprehensive M								
□ Gamma Glutamyl	STAT, Starting S, For 1 Occurrences, Blood, Venous Gamma Glutamyl Transferase (GGT) Level STAT, Starting S, For 1 Occurrences, Blood, Venous							
□ Lactate Dehydroge								
□ Creatine Kinase (0								
□ Sedimentation rate								
C Reactive Proteir	1 (CRP), Blood Level 1 Occurrences, Blood, Venous							

CONTINUED ON PAGE 2 \rightarrow

(+)

(+)

Confidentiality of this medical record shall be maintained except when use or disclosure is required or permitted by law, regulation, or written authorization by the patient.

(+)

Spectrum Health Helen DeVos

children's hospital

(+)

ABATACEPT (ORENCIA) -PEDIATRIC, OUTPATIENT, INFUSION CENTER (CONTINUED) Page 2 of 3

Patient Name		
DOB		
MRN		
Physician		
FIN		

Treatment Parameters (continued)

Treatmen	(Continued)		
	Urinalysis (UA)		
	STAT, Starting S, For 1 Occurrences, Urine, clean catch		
	Ferritin, Blood Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	Iron and Iron Binding Capacity Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	IgA, Blood Level STAT, Starting S, For 1 Occurrences, Blood, Venous		
	IgG, Blood Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	IgM, Blood Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	C3 Complement, Blood Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	C4 Complement, Blood Level		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
	Anti-dsDNA Antibody		
	STAT, Starting S, For 1 Occurrences, Blood, Venous		
Additiona	I Lab Orders		
		□ Every days	□ Until date:
□	· · · · · · · · · · · · · · · · · · ·		□ 1 year
			□ # of Treatments
		Every days	□ Until date:
		□ Once	□ 1 year
			□# of Treatments
Provider (Ordering Guidelines		
		Interval	Duration
\checkmark	ONC PROVIDER REMINDER 17	Once	1 treatment
	Orencia dosing:		
	Consider rounding dose to the nearest 250 mg vial size.		
Pre-Medic	ations		
Fie-weut	allons		
□ Pre-me	dication with dose:		
□ Pre-me	dication with dose:		
Madiaatia	20		
Medicatio	ns		
	abatacant (OPENCIA) in addium ablarida 0.0.% IV/PP		
\checkmark	abatacept (ORENCIA) in sodium chloride 0.9 % IVPB Dose:		
	□ 10 mg/kg for patients less than 75 kg		
	□ 750 mg for patients 75 to 100 kg		
	\square 1,000 mg for patients >100 kg		
	□mg/kg ORmg		
	Intravenous, Administer over 30 Minutes, Once, Starting S		

Intravenous, Administer over 30 Minutes, Once, Starting S

Nursing Orders

(+)

+

Helen DeVos/ children's hospital

 $^+$

Spectrum Health ABATACEPT (ORENCIA) -PEDIATRIC, OUTPATIENT, **INFUSION CENTER** (CONTINUED) Page 3 of 3

Patient Name		
DOB		
MRN		
Physician		
FIN		

ONC NURSING COMMUNICATION 5 \checkmark

- Please notify the Pediatric Rheumatologist attending when the patient arrives on the floor.

- Infuse through a 0.2-micron, low protein binding inline filter.

- Do not shake.

- Do not administer if solution is discolored or if foreign particulate matter is present.

- Monitor vital signs with Pulse oximetry. Obtain heart rate, respiratory rate, blood pressure and pulse oximetry and assess for symptoms of anaphylaxis every fifteen minutes through 30 minutes after drug completion.

- Notify provider, NP or PA-C and stop drug infusion immediately if patient has itching, hives, swelling, fever, rigors, dyspnea, cough or bronchospasm. Notify if greater than 20% decrease in systolic or diastolic blood pressure.

- At the end of infusion, flush secondary line with 0.9% Sodium Chloride.

- Verify that patient has diphenhydramine / Epi-pen (as appropriate) available for immediate home use. Advise patients and caregivers that reactions may occur during and after infusion including life-threatening anaphylaxis and severe hypersensitivity reactions. Inform patients of the signs and symptoms of anaphylaxis and hypersensitivity reactions and have them seek medical care should signs and symptoms occur.

- Patient to remain in the outpatient clinic for observation for minimum of 30 minutes after each infusion.

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

TRANSCRIBED:		VALIDATED:		ORDERED:			
TIME	DATE	TIME	DATE	TIME	DATE	Pager #	
	Sign		R.N. Sign		Physician Print	Physici	an

EPIC VERSION DATE: 03/19/20

+